Suppr超能文献

用于加工旋钮入孔双特异性抗体的非亲和平台。

Non-affinity platform for processing knob-into-hole bispecific antibody.

作者信息

Wang Xiaoyang, Li Min, Li Mengting, Hong Huoyan, Gao Kai, Zhao Puya

机构信息

Shanghai AsymBio Biotechnology Co., Ltd, Building 8, No.12, Lane 855, Jinzheng Road, Jinshan Industrial Park, Shanghai, China.

出版信息

Bioresour Bioprocess. 2024 Dec 18;11(1):110. doi: 10.1186/s40643-024-00827-8.

Abstract

Bispecific antibodies hold significant potential as next-generation biotherapeutics owing to their ability to simultaneously bind to two targets. However, the development of bispecific antibodies as biotherapeutics has been hindered by the high levels of byproducts produced, including both high molecular weight and low molecular weight variants. In addition, the inevitable expression of homodimers in host cells presents further obstacles to the commercial development of bispecific antibodies as therapeutics. These byproducts, which share similar physicochemical properties with the target, pose several challenges for downstream purification processes. In this study, we present a non-protein A purification platform that employ a one-step polishing chromatography to purify bispecific antibodies. Mixed-mode Capto adhere resin was used to capture the target protein at pH 7.90 ± 0.10, followed by anion exchange chromatography as a polishing step. Overall, the results of this two-step chromatography purification method demonstrated at final product purity of 98% as assessed by size-exclusion high-performance liquid chromatography (SEC-HPLC) and 98% by reversed-phase-high-performance liquid chromatography (RP-HPLC), with residual host cell proteins controlled at 10 ppm and an excellent recovery rate of approximately 60%. This study presents a non-protein A capture platform, offering a simplified, streamlined, and competitive alternative to conventional affinity chromatography.

摘要

双特异性抗体因其能够同时结合两个靶点而作为下一代生物治疗药物具有巨大潜力。然而,双特异性抗体作为生物治疗药物的开发受到了所产生的高水平副产物的阻碍,这些副产物包括高分子量和低分子量变体。此外,宿主细胞中同型二聚体的不可避免表达给双特异性抗体作为治疗药物的商业开发带来了进一步的障碍。这些与靶点具有相似物理化学性质的副产物给下游纯化过程带来了诸多挑战。在本研究中,我们提出了一种非蛋白A纯化平台,该平台采用一步精制色谱法来纯化双特异性抗体。使用混合模式的Capto adhere树脂在pH 7.90±0.10条件下捕获目标蛋白,随后进行阴离子交换色谱作为精制步骤。总体而言,这种两步色谱纯化方法的结果表明,通过尺寸排阻高效液相色谱(SEC-HPLC)评估最终产品纯度为98%,通过反相高效液相色谱(RP-HPLC)评估为98%,残留宿主细胞蛋白控制在10 ppm,回收率约为60%,效果优异。本研究提出了一种非蛋白A捕获平台,为传统亲和色谱提供了一种简化、高效且具有竞争力的替代方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c80/11655889/3a63e41561cd/40643_2024_827_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验